Quick Takeaways: Why It Matters? This partnership is designed to scale Rebound High Performance PRP across the US veterinary market by combining epiq’s distribution reach with Vetirus’s product and regulatory credentials, removing a key barrier to adoption-access to e...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
Quick Takeaways: Why It Matters? Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal. The expanded web of NDAs suggests real strategic interest ...
Quick Takeaways: Why It Matters? The partnership gives Gallant industrial‑grade cold-chain logistics, solving a key bottleneck for scaling allogeneic cell therapies beyond a few specialty centers. For MWI/Cencora, establishing -80°C capability positions the ...
